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Colorectal cancer is a common illness in the developed
world. The prognosis is highly dependent on stage at presen-
tation and surgical resectability, the main sites of relapse
being in the liver or at the anastomotic site. Overall only
35-40% of patients survive 5 years. It is estimated in the
UK that approximately 27,000 new cases will present each
year, and of these some 10,000 could be considered for
post-surgical adjuvant treatment. A number of large-scale
randomised studies have now demonstrated that chemo-
therapy offers a small but significant benefit in certain subsets
of patients, but questions of cost in terms of toxicity and the
type of patients most likely to benefit from treatment remain
unanswered. Benefit has been claimed for single-agent
5-fluorouracil (5-FU) (Buyse et al., 1988), 5-FU plus
levamisole (Laurie et al., 1989; Moertel et al., 1990) and
5-FU plus folinic acid (Wolmark et al., 1993), and studies of
5-FU plus interferon are currently under way. Following the
publication of Moertel's data, 5-FU plus levamisole was the
subject of a 'clinical alert' from the National Cancer Institute
(USA) and led to the rapid acceptance of this regimen as
standard adjuvant therapy for this disease in the US (Con-
sensus Statements, 1990).
This was not universally accepted by the European onco-
logical community, but did result in the unfortunate
premature closure of a number of European adjuvant studies
(Zaniboni et al., 1993), mainly because it was felt to be
unethical not to offer some adjuvant therapy, i.e. 'control
arms' were difficult to justify. Why was this regimen not
universally accepted? What has happened since to produce
uncertainty in the minds of oncologists?
Many reasons could be cited for European conservatism in
the face of the NCI consensus statement. In the UK, at least,
levamisole has never been licensed for this application, and
has now been withdrawn completely from all but clinical trial
use (having been previously available on the named-patient
basis at the discretion of oncologists). The claimed immuno-
modulator effects of levamisole have been difficult to sub-
stantiate (Stevenson et al., 1991) and appear more significant
at dose levels higher than used in most clinical trials to date
(Janik et al., 1993). Single-agent levamisole appears to have
no anti-tumour activity (Moertel et al., 1990; Arnaud et al.,
1989) in its own right, which is counterintuitive, at least if the
example of breast cancer adjuvant therapy is considered, but
does not rule out an effect of the combination by an as yet
unexplained mechanism. The pivotal trials on which the
foundations of the NCI consensus were laid also served to
confuse by presenting subgroup analyses in Dukes B patients
with no apparent benefit from adjuvant therapy. Although
this was likely to be a problem of statistical interpretation
(the numbers of events were too small in this subset), this
was again counterintuitive and further complicated the whole
issue in the minds of European oncologists.
A number of advances have occurred since the 'consensus'.
Our understanding of immunopharmacology has increased
steadily, and more has been learned of the putative immuno-
stimulatory actions of levamisole (De Brabander et al., 1992).
The possibility of an interaction with histocompatibility
antigens and NK-cell activity does seem likely, and new
studies with levamisole should include investigation of
mechanism of action (Goodrich et al., 1993). Folinic acid
modulation of 5-FU activity has shown definite improve-
ments in the setting of advanced disease (Advanced Colorec-
tal Cancer Meta-Analysis Project, 1992), and this has led to a
profusion of European and US adjuvant trials of various
combinations and schedules of 5-FU, folinic acid and levami-
sole. In addition, some alarm bells are beginning to sound on
the possibility of adverse effects of levamisole with long-term
or high-dose usage. Multifocal leukoencephalopathy has been
reported in a small number of patients (Kimmel & Schutt,
1993). Hepatotoxicity of a mild and reversible nature is a
common problem and can cause confusion owing to sus-
picion of hepatic relapse (Moertel et al., 1993). In this issue
of the BJC the paper by Chlebowski et al. (1994) raises more
concern over levamisole use in humans. They have demon-
strated in a small group of patients given levamisole vs
placebo that after 5 years' follow-up there is an apparent
excess of cancer- and non-cancer-related deaths. However, in
view of the small numbers involved, it is not possible to be
absolutely sure of this association (as conceded by the
authors in the discussion of their results).
In the light of these findings it was perhaps reasonable to
be conservative, rather than to accept universally 5-FU plus
levamisole as the standard of care. This cautious attitude
should also be borne in mind with the new intensive dosing
schedules of levamisole in some current US trials. How can
we now resolve the issue of the place of levamisole in this
disease setting? The answer (as usual) is to conduct large,
well-organised, randomised trials to address specific ques-
tions. It would appear that none of the large US col-
laborative groups or the European organisations wishes to
reproduce the Laurie or Moertel studies, and this is under-
standable in view of the exciting data emerging for 5-FU plus
folinic acid in advanced disease. Some of the answers may
come indirectly from ongoing US adjuvant trials of 5-FU +
folinic acid ± levamisole. A UK national adjuvant trial
(QUASAR) has recently been launched under the auspices of
the UK CCCR. A 2 x 2 factorial design has been adopted
comparing 5-FU with high- and low-dose L-folinic acid plus
or minus levamisole, and it is hoped that with a projected
accrual of 6,000-8,000 patients this may help to sort out the
benefit (or lack of benefit) of levamisole in this disease set-
ting.
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